JP2016536020A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536020A5
JP2016536020A5 JP2016552471A JP2016552471A JP2016536020A5 JP 2016536020 A5 JP2016536020 A5 JP 2016536020A5 JP 2016552471 A JP2016552471 A JP 2016552471A JP 2016552471 A JP2016552471 A JP 2016552471A JP 2016536020 A5 JP2016536020 A5 JP 2016536020A5
Authority
JP
Japan
Prior art keywords
seq
set forth
variable region
chain variable
region set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016552471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536020A (ja
JP6515111B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/en
Publication of JP2016536020A publication Critical patent/JP2016536020A/ja
Publication of JP2016536020A5 publication Critical patent/JP2016536020A5/ja
Application granted granted Critical
Publication of JP6515111B2 publication Critical patent/JP6515111B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016552471A 2013-11-06 2014-11-05 新規の抗クローディン抗体および使用方法 Expired - Fee Related JP6515111B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900916P 2013-11-06 2013-11-06
US61/900,916 2013-11-06
PCT/US2014/064165 WO2015069794A2 (en) 2013-11-06 2014-11-05 Novel anti-claudin antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2016536020A JP2016536020A (ja) 2016-11-24
JP2016536020A5 true JP2016536020A5 (enExample) 2017-08-10
JP6515111B2 JP6515111B2 (ja) 2019-05-22

Family

ID=53042314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552471A Expired - Fee Related JP6515111B2 (ja) 2013-11-06 2014-11-05 新規の抗クローディン抗体および使用方法

Country Status (18)

Country Link
US (2) US10053511B2 (enExample)
EP (1) EP3065776A4 (enExample)
JP (1) JP6515111B2 (enExample)
KR (1) KR20160070191A (enExample)
CN (1) CN105813650A (enExample)
AR (1) AR102554A1 (enExample)
AU (1) AU2014346792A1 (enExample)
BR (1) BR112016010169A2 (enExample)
CA (1) CA2928671A1 (enExample)
CL (1) CL2016001102A1 (enExample)
IL (1) IL245237A0 (enExample)
MX (1) MX2016005763A (enExample)
PE (1) PE20160870A1 (enExample)
PH (1) PH12016500781A1 (enExample)
RU (1) RU2016122041A (enExample)
SG (1) SG11201603397QA (enExample)
WO (1) WO2015069794A2 (enExample)
ZA (1) ZA201603308B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
CN105940107B (zh) 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
AU2016364853A1 (en) * 2015-12-04 2018-06-21 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3049727C (en) * 2017-01-13 2022-10-04 Vasomune Therapeutics Inc. An agent for promoting angiogenesis and methods and uses thereof
MX2020002921A (es) * 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.
WO2019065964A1 (ja) 2017-09-29 2019-04-04 第一三共株式会社 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
BR112021003018A2 (pt) * 2018-08-21 2021-05-11 Albert Einstein College Of Medicine anticorpos monoclonais contra tim-3 humana
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン6抗体及びその使用
SI3941946T1 (sl) 2019-03-20 2025-09-30 The Regents Of The University Of California Protitelesa proti klavdinu-6 in konjugati zdravil
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
CN117659190A (zh) * 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
WO2020237088A1 (en) * 2019-05-21 2020-11-26 University Of Miami Treatment of sensorineural deafness
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
WO2021060914A1 (ko) * 2019-09-26 2021-04-01 (재)록원바이오융합연구재단 항-클라우딘-3 키메라 항원 수용체
US20230220066A1 (en) 2020-03-31 2023-07-13 Chugai Seiyaku Kabushiki Kaisha Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
CN116940377A (zh) * 2021-03-05 2023-10-24 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
WO2022268200A1 (zh) * 2021-06-25 2022-12-29 信达生物制药(苏州)有限公司 针对密蛋白18.2的抗体及其用途
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
US12049502B2 (en) 2022-11-30 2024-07-30 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024227424A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 hCLDN6的抗原结合蛋白和其用途
WO2024243561A1 (en) 2023-05-25 2024-11-28 The Regents Of The University Of California Methods of treating cancer

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5191066A (en) 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20020192209A1 (en) 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
WO1999037779A1 (en) 1998-01-22 1999-07-29 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
DE69907977T2 (de) 1998-08-27 2004-07-22 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
US6756356B2 (en) 1998-11-03 2004-06-29 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
US7026449B2 (en) 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
AU2004239301B2 (en) 2003-05-09 2010-08-19 Diadexus, Inc. OVR110 antibody compositions and methods of use
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ATE542821T1 (de) 2004-03-01 2012-02-15 Spirogen Ltd 11-hydroxy-5h-pyrroloä2,1-cüä1,4übenzodiazepin- - on derivate als zwischenverbindungen für die herstellung von c2 substituierten pyrrolobenzodiazepinen
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン,エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
PL2032606T3 (pl) 2006-05-30 2014-04-30 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowania
CN101501187A (zh) 2006-06-06 2009-08-05 田纳西大学研究基金会 富含赘生干细胞的组合物及包含其的方法
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
ES2987072T3 (es) 2006-09-07 2024-11-13 Scott & White Memorial Hospital Métodos y composiciones basados en conjugados de toxina diftérica-interleucina-3
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
AU2008207945A1 (en) 2007-01-22 2008-07-31 Macrogenics West, Inc. Human cancer stem cells
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
SG173444A1 (en) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
NZ734307A (en) * 2009-11-11 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
ES2668645T3 (es) * 2010-02-08 2018-05-21 Agensys, Inc. Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
PT2536399T (pt) 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
MX2012011900A (es) 2010-04-15 2013-03-21 Seattle Genetics Inc Conjugados de pirrolobenzodiazepina diana.
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
US20130259806A1 (en) 2010-12-09 2013-10-03 David Light Dimeric molecular complexes with free cysteine residues and conjugates thereof
DK2681244T3 (da) 2011-03-02 2018-01-29 Roche Glycart Ag Cea-antistoffer
NZ706004A (en) 2011-05-13 2016-12-23 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
MX369276B (es) 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
SG10201706468RA (en) 2013-02-08 2017-09-28 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
EP3470513B1 (en) 2013-03-15 2020-05-13 Expression Pathology, Inc. Srm assay to indicate cancer therapy
JP6660294B2 (ja) 2013-06-04 2020-03-11 シトムクス セラピューティクス,インコーポレイティド 活性化可能抗体を結合するための組成物及び方法
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
EP4190809A1 (en) 2014-02-11 2023-06-07 Seagen Inc. Selective reduction of proteins
FI3708579T3 (fi) 2014-04-01 2024-07-16 Biontech Cell & Gene Therapies Gmbh Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2016536020A5 (enExample)
JP2016531915A5 (enExample)
CN111148761B (zh) 多特异性抗体及其制备和使用方法
JP2017500028A5 (enExample)
JP2016538318A5 (enExample)
JP2015509947A5 (enExample)
HRP20240924T1 (hr) Anti - sirpalpha antitijela
JP2019532056A5 (enExample)
JP2016531914A5 (enExample)
JP2017534256A5 (enExample)
JP2017535246A5 (enExample)
CN115003333A (zh) Pvrig结合蛋白及其医药用途
JP2015509948A5 (enExample)
JP2020501531A5 (enExample)
CN111110862A (zh) 抗cldn18.2抗体的药物偶联体及其制备方法和用途
JP2016503067A5 (enExample)
CA3146341A1 (en) Bispecific anti lrrc15 and cd3epsilun antibudies
JP2017535257A5 (enExample)
JP2017518040A5 (enExample)
JP2015509938A5 (enExample)
HRP20202047T1 (hr) Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma
HRP20191169T1 (hr) Konjugati antidll3-protutijelo-pbd i njihove uporabe
JP2016505546A5 (enExample)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
CN116041530A (zh) 多特异性抗体及其制备和使用方法